Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brolucizumab for Dystrophy-Related Macular Neovascularization
NCT04690062Phase 4Unknown
- Sponsor
- Benha University
- Start
- Oct 2020
- Primary completion
- Dec 2022
- Modality
- scFv Fragments, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of brolucizumab in macular neovascularization (MNV), sponsored by Benha University. Status: unknown.
02
Drugs
brolucizumab
03
Conditions
macular neovascularization (MNV)
Beyond the preview
Go deeper on NCT04690062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04690062.